<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02657759</url>
  </required_header>
  <id_info>
    <org_study_id>DPlantes</org_study_id>
    <nct_id>NCT02657759</nct_id>
  </id_info>
  <brief_title>EFFECTS OF CARDICHOL, AN HERBAL DIETARY SUPPLEMENT, IN MODERATE HYPERCHOLESTEROLEMIA</brief_title>
  <acronym>CARDICHOL 1</acronym>
  <official_title>EFFECTS OF CARDICHOL, AN HERBAL DIETARY SUPPLEMENT, IN MODERATE HYPERCHOLESTEROLEMIA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Direct Plantes</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Direct Plantes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research aims to evaluate the effect of CARDICHOL chronic consumption (12 weeks) on&#xD;
      lipid metabolism and especially on blood LDL cholesterol in volunteers with moderate&#xD;
      hypercholesterolemia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">May 2016</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of the fasting blood LDL cholesterol NCEP concentration</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of the fasting blood LDL cholesterol concentration (NCEP and Friedewald estimation methods)</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the fasting blood LDL cholesterol concentration (Friedewald estimation method)</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the fasting blood LDL cholesterol concentration (NCEP and Friedewald estimation methods)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the fasting blood HDL cholesterol concentration (NCEP and direct methods)</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the fasting blood HDL cholesterol concentration (NCEP and direct methods)</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the fasting blood HDL cholesterol concentration (NCEP and direct methods)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the fasting blood total cholesterol concentration</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the fasting blood total cholesterol concentration</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the fasting blood total cholesterol concentration</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the fasting blood triglycerides concentration</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the fasting blood triglycerides concentration</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the fasting blood tiglycerides concentration</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the fasting blood apolipoprotein B100 concentration</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the fasting blood apolipoprotein B100 concentration</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the fasting blood apolipoprotein B100 concentration</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the fasting blood glucose concentration</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the fasting blood glucose concentration</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the fasting blood glucose concentration</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the fasting blood hsCRP concentration</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the fasting blood hsCRP concentration</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the fasting blood hsCRP concentration</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the ratio of fasting blood concentrations LDLox/LDLc (NCEP method)</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the fasting arylesterase activity (PON-1) in blood</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Complete blood count</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Blood Aspartate Amino Transferase</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Blood Alanine Amino Transferase</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Blood Gamma Glutamyl Transpeptidase</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Blood total bilirubin</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Blood creatinine</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Blood urea</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Blood Lactate Deshydrogenase</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Blood Creatine Kinase</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Glycated hemoglobin</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Heart rate</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Systolic Blood Pressure</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Diastolic Blood Pressure</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Body weight</measure>
    <time_frame>4 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Body weight</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Body weight</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Physical Activity Score</measure>
    <time_frame>4 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Physical Activity Score</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Physical Activity Score</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Total energy intake</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of energy intake from fat</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Dietary fiber intake</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Saturated Fatty Acids intake</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>HYPERCHOLESTEROLEMIA</condition>
  <arm_group>
    <arm_group_label>CARDICHOL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Food supplement formula in shape of pill called CARDICHOL. 2 pills daily during 12 weeks (from visit V1 to visit V4). One pill immediately before, after or during breakfast and lunch.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo with the same characteristics, appearance, packaging, and composition as the active formula, except for active ingredients replaced by dicalcium phosphate and flavouring substances.&#xD;
2 pills daily during 12 weeks (from visit V1 to visit V4). One pill immediately before, after or during breakfast and lunch.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>CARDICHOL</intervention_name>
    <arm_group_label>CARDICHOL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>PLACEBO</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        To be eligible to the study, male and female volunteers will have to fulfill the following&#xD;
        criteria (assessment based on the medical examination performed at V0 with a checking at&#xD;
        V1):&#xD;
&#xD;
          -  Age between 18 and 65 years (limits included).&#xD;
&#xD;
          -  BMI between 18,5 and 30 kg/m² (limits excluded).&#xD;
&#xD;
          -  For women: Non menopausal with the same reliable contraception since at least three&#xD;
             cycles before the beginning of the study and agreeing to keep it during the entire&#xD;
             duration of the study (condom alone without spermicide gel excluded) or menopausal&#xD;
             without or with hormone replacement therapy (oestrogenic replacement therapy begun&#xD;
             from less than 3 month excluded).&#xD;
&#xD;
          -  Good general and mental health with in the opinion of the investigator: no clinically&#xD;
             significant and relevant abnormalities of medical history or physical examination.&#xD;
&#xD;
          -  Able and willing to participate to the study by complying with the protocol procedures&#xD;
             as evidenced by his dated and signed informed consent form.&#xD;
&#xD;
          -  Affiliated with a social security scheme.&#xD;
&#xD;
          -  Agree to be registered on the volunteers in biomedical research file.&#xD;
&#xD;
        After V0 biological analysis the subjects will be eligible to the study on the following&#xD;
        criteria:&#xD;
&#xD;
        - Fasting blood LDLc level (Friedewald estimation method) between 1,3 and 2,2g/L (limits&#xD;
        included with ± 2% tolerated around).&#xD;
&#xD;
        A re-screening can occur from 2 months after the exit of study for failure to comply with&#xD;
        the one or more of the eligibility criteria listed above.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Volunteers with the following criteria will be considered as non eligible to the study&#xD;
        (assessment based on the medical examination performed at V0 with a checking at V1):&#xD;
&#xD;
          -  Suffering from a metabolic disorder such as diabetes, uncontrolled thyroidal trouble&#xD;
             or other metabolic disorder.&#xD;
&#xD;
          -  Suffering from a severe chronic disease (e.g. cancer, HIV, renal failure, hepatic or&#xD;
             biliary disorders ongoing, chronic inflammatory digestive disease, arthritis or other&#xD;
             chronic respiratory trouble, etc.) or gastrointestinal disorders found to be&#xD;
             inconsistent with the conduct of the study by the investigator (e.g. celiac disease).&#xD;
&#xD;
          -  With a history of ischemic cardiovascular event or, during the previous 6 months a&#xD;
             surgical procedure.&#xD;
&#xD;
          -  Suffering from an uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg and/or&#xD;
             diastolic blood pressure ≥ 100 mmHg).&#xD;
&#xD;
          -  With a known or suspected food allergy or intolerance or hypersensitivity to any of&#xD;
             the study products' ingredient.&#xD;
&#xD;
          -  Pregnant or lactating women or intending to become pregnant within 4 months ahead.&#xD;
&#xD;
          -  Requiring a cholesterol lowering by immediate pharmacologic intervention according to&#xD;
             the current recommendations (AFSSAPS 2005).&#xD;
&#xD;
          -  Under lipid-lowering treatment (e.g. statins, fibrates, ezetimibe, bile acid&#xD;
             sequestrants, niacin, etc.) or stopped less than 4 months before the randomization.&#xD;
&#xD;
          -  Under medication which could affect blood lipid parameters (e.g. long-term&#xD;
             corticosteroid systemic drug, systemic antibodies, androgens or phenytoin, etc.) or&#xD;
             stopped less than 1 month before the randomization (stable long-term treatment with&#xD;
             beta blocker or thiazide diuretics tolerated).&#xD;
&#xD;
          -  Regular intake of dietary supplements or &quot;health foods&quot; which are known to decrease&#xD;
             LDLc or triglycerides (e.g. rich in plant stanol or sterol like PRO-ACTIV or DANACOL&#xD;
             products, red yeast rice, policosanol, capsules containing omega-3 fatty acids from&#xD;
             fish oils, etc.) or stopped less than 3 months before the randomization.&#xD;
&#xD;
          -  Under treatment or dietary supplement which could significantly affect parameter(s)&#xD;
             followed during the study according to the investigator or stopped in a too short&#xD;
             period before the randomization.&#xD;
&#xD;
          -  With significant change in food habits or in physical activity in the 3 months before&#xD;
             randomization or not agreeing to keep them unchanged throughout the study.&#xD;
&#xD;
          -  With reported body weight variation &gt; 5% in the 3 months prior the randomization or&#xD;
             with a hyper or hypocaloric diet planned in the next 4 months.&#xD;
&#xD;
          -  With a personal history of anorexia nervosa, bulimia or significant eating disorders&#xD;
             according to the investigator.&#xD;
&#xD;
          -  Consuming more than 3 standard drinks of alcoholic beverage for men or 2 standard&#xD;
             drinks daily for women or not agreeing to keep his alcohol consumption habits&#xD;
             unchanged throughout the study.&#xD;
&#xD;
          -  Smoking more than 10 cigarettes daily or not agreeing to keep his smoking habits&#xD;
             unchanged throughout the study.&#xD;
&#xD;
          -  Having a lifestyle deemed incompatible with the study according to the investigator&#xD;
             including high level physical activity (defined as more than 10 hours of significant&#xD;
             physical activity a week, walking excluded).&#xD;
&#xD;
          -  Who made a blood donation in the 3 months before the randomization or intending to&#xD;
             make it within 5 months ahead.&#xD;
&#xD;
          -  Taking part in another clinical trial or being in the exclusion period of a previous&#xD;
             clinical trial.&#xD;
&#xD;
          -  Having received, during the last 12 months, indemnities for clinical trial higher or&#xD;
             equal to 4500 Euros.&#xD;
&#xD;
          -  Under legal protection (guardianship, wardship) or deprived from his rights following&#xD;
             administrative or judicial decision.&#xD;
&#xD;
          -  Presenting a psychological or linguistic incapability to sign the informed consent.&#xD;
&#xD;
          -  Impossible to contact in case of emergency.&#xD;
&#xD;
        After V0 biological analysis the subjects will be considered as non eligible to the study&#xD;
        on the following criteria:&#xD;
&#xD;
          -  Fasting blood glucose level &gt; 1,26 g/L (6,99 mmol/L).&#xD;
&#xD;
          -  Fasting blood triglycerides &gt; 3,5 g/L (3,95 mmol/L).&#xD;
&#xD;
          -  Fasting blood TC &gt; 4,5 g/L or HDLc &lt; 0,1 g/L with an abnormality judged as clinically&#xD;
             significant according to the investigator.&#xD;
&#xD;
          -  Blood AST &gt; 1,68 µkat/L, ALT &gt; 1,70 µkat/L or GGT &gt; 2,55 µkat/L (values corresponding&#xD;
             to 2,5xULN).&#xD;
&#xD;
          -  Blood urea &gt; 12,11 mmol/L (value corresponding to 1,5xULN) or creatinine &gt; 125 µmol/L.&#xD;
&#xD;
          -  Complete blood count with hemoglobin &lt; 11 g/L or leucocytes &lt; 3000 / mm3 or leucocytes&#xD;
             &gt; 16000 /mm3 or clinically significant abnormality according to the investigator.&#xD;
&#xD;
        A re-screening can occur from 2 months after the exit of study for failure to comply with&#xD;
        the one or more of the eligibility criteria listed above.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrice CHAUVEAU</last_name>
    <role>Study Director</role>
    <affiliation>BioFortis</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patrice CHAUVEAU</last_name>
    <phone>+ 33 (0)2 40 20 45 65</phone>
    <email>patrice.chauveau@mxns.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Biofortis</name>
      <address>
        <city>Saint-Herblain</city>
        <zip>44800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrice CHAUVEAU</last_name>
      <phone>+ 33 (0)2 40 20 45 65</phone>
      <email>patrice.chauveau@mxns.com</email>
    </contact>
    <investigator>
      <last_name>David GENDRE, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <study_first_submitted>January 14, 2016</study_first_submitted>
  <study_first_submitted_qc>January 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2016</study_first_posted>
  <last_update_submitted>January 19, 2016</last_update_submitted>
  <last_update_submitted_qc>January 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

